Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group

Alberts, David S.; Jiang, Caroline S.; Liu, P. Y.; Wilczynski, Sharon P.; Markman, Maurie; Rothenberg, Mace L.

doi:10.1111/j.1048-891x.2004.014204.x

Cited by 18 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite its tolerability, PLD as a consolidation agent fa i le d to demonst rate a n i mpact on DFS or OS at t he dosage and schedule used in this study. Although the 2-year OS rate of 62% is similar to that previously published for Southwest Oncology Group studies (64%) in suboptimally debulked patients using oral altretamine consolidation therapy [11,12], no difference in survival was noted. The GOG 111 study by McGuire et al [3] also evaluated stage III/IV suboptimally debulked EOC patients treated with cisplatin plus either cyclophosphamide or paclitaxel.…”

Section: Discussionsupporting

confidence: 82%

Pegylated Liposomal Doxorubicin Consolidation Therapy after Platinum/Paclitaxel-Based Chemotherapy for Suboptimally Debulked, Advanced-Stage Epithelial Ovarian Cancer Patients

et al. 2006

View full text Add to dashboard Cite

Objective. To assess the feasibility of using pegylated liposomal doxorubicin (PLD) as a consolidation therapy in patients with advanced ovarian cancer who have attained a clinically defined complete response to initial platinum/paclitaxel-based chemotherapy.Methods. Patients diagnosed with suboptimally debulked stage IIIC/IV epithelial ovarian cancer who attained a clinically defined complete response at the completion of platinum/paclitaxel-based chemotherapy were eligible for this protocol. Patients were treated with PLD at a dose of 40 mg/m 2 every 28 days for four cycles. A survival analysis was calculated using the KaplanMeier method.Results. Of the 30 patients enrolled, 29 were evaluable. Twenty-three patients (79%) completed all four cycles of consolidation therapy. Palmar-plantar erythrodysesthesia was the most common toxicity. Six patients remained clinically without evidence of disease with a median follow-up of 35 months from the completion of primary chemotherapy. The median progression-free interval was 15 months, and median overall survival time was 31 months, with 47% of patients achieving a 4-year survival.Conclusions. Consolidation therapy with PLD chemotherapy administered to women with advanced epithelial ovarian cancer after initial chemotherapy appears feasible based on its toxicity profile. Considering the tolerability of this agent, further investigation is needed to depict the optimal dose and schedule needed for consolidation therapy.

show abstract

Section: Discussionsupporting

confidence: 82%

Pegylated Liposomal Doxorubicin Consolidation Therapy after Platinum/Paclitaxel-Based Chemotherapy for Suboptimally Debulked, Advanced-Stage Epithelial Ovarian Cancer Patients

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Vergote et al reported a 14% response rate of HMM as a single agent in 50 patients with pltinum-resistant disease. And oral altretamine 260 mg/m 2 /day was given for 14 days every 4 weeks for six cycles to patients with FIGO stage III EOC who obtained a clinical response following platinum-based therapy (12). To date, however, there have been no trials comparing HMM with no treatment in patients with advanced EOC.…”

Section: Discussionmentioning

confidence: 99%

“…Consolidation therapy uses one or more of the multiple chemotherapeutic agents known to be active in recurrent disease (5, 6). One of these agents, hexamethylmelamine (HMM), which has been used to treat recurrent ovarian cancer for many years, is well tolerated (7-11) and is associated with prolonged PFS and OS in the Phase II setting (12). Little is known, however, about outcomes of consolidation therapy in advanced EOC patients; and there have been no comparison studies of HMM consolidation therapy in these patients.…”

Section: Introductionmentioning

confidence: 99%

Hexamethylmelamine as Consolidation Treatment for Patients with Advanced Epithelial Ovarian Cancer in Complete Response after First-Line Chemotherapy

et al. 2009

View full text Add to dashboard Cite

The aim of this study was to assess the efficacy of consolidation therapy with hexamethylmelamine (HMM) in patients with advanced epithelial ovarian cancer (EOC). Patients treated at our hospital between January 1997 and November 2006 and in documented clinical complete response from advanced ovarian cancer following front-line platinum-based therapy were retrospectively analyzed. The patients treated with HMM were compared to the patients of matched counterpart without consolidation therapy. Of 102 patients enrolled, 49 were treated with HMM and 53 received no consolidation treatment. For patients with HMM and observed patients, the mean age were 54.6 and 55.6 yr; the distribution of stage was similar (P=0.977); the optimal surgery was performed in 36 (73.5%) and 44 (83%) (P=0.336); the recurrence rate were 27 (55.1%) and 33 (62.3%) (P=0.463); and the median progression-free survival were 38 months and 21 months for patients with HMM and observed patients (P=0.235). No treatment-related adverse events were reported during the follow-up period. Although this study failed to show the significant survival benefit of consolidation therapy with HMM in patients with advanced EOC, we consider that our study can contribute data to investigate the effectiveness of consolidation therapy in epithelial ovarian cancer.

show abstract

“…Nab-paclitaxel has an overall response rate of 64%. 126 Altretamine has a 14% response rate 127 and ifosfamide a 12% response rate, 128 although less information is available regarding their use in patients who are refractory to paclitaxel. Bevacizumab is also active (21%) in both platinum-sensitive and platinum-resistant patients, [129][130][131][132][133] although it may cause arterial thrombosis or intestinal perforation.…”

Section: Recurrent Diseasementioning

confidence: 99%

Epithelial Ovarian Cancer

Morgan¹,

Alvarez²,

Armstrong³

et al. 2011

J Natl Compr Canc Netw

View full text Add to dashboard Cite

Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group

Abstract: Consolidation therapy with oral altretamine was generally well tolerated and associated with prolonged progression-free and overall survival in the Phase II setting.

Cited by 18 publications

References 20 publications

Pegylated Liposomal Doxorubicin Consolidation Therapy after Platinum/Paclitaxel-Based Chemotherapy for Suboptimally Debulked, Advanced-Stage Epithelial Ovarian Cancer Patients

Pegylated Liposomal Doxorubicin Consolidation Therapy after Platinum/Paclitaxel-Based Chemotherapy for Suboptimally Debulked, Advanced-Stage Epithelial Ovarian Cancer Patients

Hexamethylmelamine as Consolidation Treatment for Patients with Advanced Epithelial Ovarian Cancer in Complete Response after First-Line Chemotherapy

Epithelial Ovarian Cancer

Contact Info

Product

Resources

About